Evidence map›Paper›PMID 39485703›Full record

ArticleJournal of the American Society of Nephrology : JASN2024

Arteriovenous Access Creation and eGFR Decline in Patients with CKD.

Abdel-Hay Tabcheh, Raphaël Coscas, Oriane Lambert, Bénédicte Stengel, Luc Frimat, Ziad Massy, Christian Combe, Murilo Guedes, Roberto Pecoits-Filho, Julie Boucquemont and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The Potential Outcome-Modification Influences Introduced by ESKD Life Plan on eGFR Slopes.Journal of the American Society of Nephrology : JASN · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abdel-Hay TabchehCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID 0009-0003-6074-2903
Raphaël CoscasCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID 0000-0002-4428-2877
Oriane LambertCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID 0000-0002-0281-1881
Bénédicte StengelCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID 0000-0001-9469-0804
Luc FrimatService de Néphrologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.
Ziad MassyCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.
Christian CombeNephrology, Transplantation, Dialysis, and Apheresis Department, Bordeaux University Medical Center, Bordeaux University, Bordeaux, France.ORCID 0000-0002-0360-573
Murilo GuedesArbor Research Collaborative for Health, Ann Arbor, Michigan.ORCID 0000-0002-3495-852
Roberto Pecoits-FilhoArbor Research Collaborative for Health, Ann Arbor, Michigan.ORCID 0000-0002-0255-6710
Julie BoucquemontCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID 0000-0001-5874-8845
Natalia Alencar De PinhoCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, INSERM U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France.ORCID 0000-0002-0438-6487
CKD-REIN Study Collaborators

Funding

Agence Nationale de la Recherche (ANR) through the 2010 «Cohortes- Investissements d'Avenir » program (ANR-IA-COH-2012/3731), private partnership with Fresenius Medical Care and GlaxoSmithKline (GSK) since 2012 and Vifor France from 2018 to 2023, Sanofi-Genzyme from 2012 to 2015, Baxter and Merck Sharp & Dohme-Chibret (MSD France) from 2012 to 2017, Amgen from 2012 to 2020, Lilly France from 2013 to 2018, Otsuka Pharmaceutical from 2015 to 2020, AstraZeneca from 2018 to 2021 and Boehringer Ingelheim France since 2022.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39485703
PMCPMC11543006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.